Axogen Company Leadership
| AXGN Stock | USD 16.59 0.15 0.90% |
Axogen employs about 451 people. The company is managed by 21 executives with a total tenure of roughly 48 years, averaging almost 2.0 years of service per executive, having 21.48 employees per reported executive. Analysis of Axogen's management performance can provide insight into the firm performance.
| Karen Zaderej CEO CEO and President and Director |
| Angelo Scopelianos President Vice President - Research & Development |
Axogen Management Team Effectiveness
Axogen's management efficiency ratios could be used to measure how well Axogen manages its routine affairs as well as how well it operates its assets and liabilities.Axogen Workforce Comparison
Axogen Inc is rated third in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 6,128. Axogen holds roughly 451 in number of employees claiming about 7% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.02) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.03 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.03. Axogen Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Axogen insiders, such as employees or executives, is commonly permitted as long as it does not rely on Axogen's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Axogen insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Burke William P. Mr. over two weeks ago Disposition of 2400 shares by Burke William P. Mr. of Axogen at 18.01 subject to Rule 16b-3 | ||
Levine Alan M over three months ago Acquisition by Levine Alan M of 14150 shares of Axogen subject to Rule 16b-3 | ||
Hartley Lindsey Marie over three months ago Insider Trading | ||
Thomas Paul over three months ago Acquisition by Thomas Paul of 18867 shares of Axogen subject to Rule 16b-3 | ||
Tyndall Joseph A. over three months ago Disposition of 26931 shares by Tyndall Joseph A. of Axogen at 10.72 subject to Rule 16b-3 | ||
Johnson John over three months ago Disposition of 4073 shares by Johnson John of Axogen at 10.61 subject to Rule 16b-3 | ||
Tyndall Joseph A. over three months ago Disposition of 12850 shares by Tyndall Joseph A. of Axogen at 6.3 subject to Rule 16b-3 | ||
Tyndall Joseph A. over three months ago Disposition of 2525 shares by Tyndall Joseph A. of Axogen at 11.63 subject to Rule 16b-3 |
Axogen Notable Stakeholders
An Axogen stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Axogen often face trade-offs trying to please all of them. Axogen's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Axogen's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Michael Dale | CEO President | Profile | |
| Karen Zaderej | CEO and President and Director | Profile | |
| Angelo Scopelianos | Vice President - Research & Development | Profile | |
| Erick DeVinney | Vice President of Clinical and Translational Sciences | Profile | |
| Peter Mariani | Ex CFO | Profile | |
| Marc Began | General VP | Profile | |
| Gregory Davault | VP Marketing | Profile | |
| Maria Martinez | Chief Human Resource Officer | Profile | |
| Lindsey CPA | Chief Officer | Profile | |
| CFA CPA | Chief Officer | Profile | |
| Isabelle Billet | Chief Strategy and Business Development Officer | Profile | |
| Jens Kemp | Chief Officer | Profile | |
| Todd Puckett | Vice Operations | Profile | |
| Harold MBA | Vice Relations | Profile | |
| Craig Swandal | Vice Operations | Profile | |
| Bradley JD | G Officer | Profile | |
| Ed Joyce | Director Relations | Profile | |
| Michael Donovan | Vice Operations | Profile | |
| Doris Quackenbush | Vice Sales | Profile | |
| Ivica MD | Chief Officer | Profile | |
| Harold Tamayo | Vice Relations | Profile |
About Axogen Management Performance
The success or failure of an entity such as Axogen Inc often depends on how effective the management is. Axogen management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Axogen management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Axogen management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 428 people.
Axogen Workforce Analysis
Traditionally, organizations such as Axogen use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Axogen within its industry.Axogen Manpower Efficiency
Return on Axogen Manpower
| Revenue Per Employee | 415.4K | |
| Revenue Per Executive | 8.9M | |
| Net Loss Per Employee | 22.1K | |
| Net Loss Per Executive | 474.5K | |
| Working Capital Per Employee | 152.1K | |
| Working Capital Per Executive | 3.3M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axogen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Stock space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axogen. If investors know Axogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axogen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Axogen Inc is measured differently than its book value, which is the value of Axogen that is recorded on the company's balance sheet. Investors also form their own opinion of Axogen's value that differs from its market value or its book value, called intrinsic value, which is Axogen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axogen's market value can be influenced by many factors that don't directly affect Axogen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Axogen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Axogen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.